Spaq Co
Spaq Co
Spaq Co
This patient information leaflet focuses on uses of the medicine covered by WHO’s Prequalification Team -
Medicines. The recommendations for use are based on WHO guidelines and on information from stringent
regulatory authorities (term to be revised).
The medicine may be authorised for additional or different uses by national medicines regulatory
authorities.
Page 1 of 7
Amodiaquine( as hydrochloride) 153mg Dispersible Tablets + WHOPAR Part 3 January 2019
Pyrimethamine/Sulfadoxine 25mg/500mg Dispersible Tablets
(Guilin Pharmaceuticals Co., Ltd.) MA117
Read all of this leaflet carefully before you start taking this medicine because it contains important
information for you.
- Keep this leaflet. You may need to read it again.
- If you have questions about the medicine, ask your health care provider.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if
their signs of illness seem to be the same as yours.
- If you get any side effects, talk to your health care provider. This includes unwanted effects not listed
in this leaflet. See section 4.
SPAQ-CO® Disp 153mg+25mg/500mg contains two types of tablets. One contains a medicine called
amodiaquine and the other contains two medicines: pyrimethamine and sulfadoxine.
SPAQ-CO® Disp 153mg+25mg/500mg is used to prevent malaria in children aged between 12 and 59
months during the malaria season (usually during the rainy season). SPAQ-CO® Disp 153mg+25mg/500mg
is for use by children in the Sahel sub-region of Africa.
The health care provider will use the most recent official guidelines on the use of malaria medicines to check
that the medicine is the right one and on when to start giving it to your child.
2. What you need to know before you take SPAQ-CO® Disp 153mg+25mg/500mg
Your child must not be given SPAQ-CO® Disp 153mg+25mg/500mg if your child:
• is allergic (hypersensitive) to amodiaquine, pyrimethamine, sulfadoxine (or another sulphonamide) or to
any of the other ingredients of SPAQ-CO® Disp 153mg+25mg/500mg (see section 6 What SPAQ-CO®
Disp 153mg+25mg/500mg contains).
• has ever suffered blood disorders with amodiaquine, pyrimethamine or sulfadoxine.
• has ever had liver problems with amodiaquine.
1
Trade names are not prequalified by WHO. This is the national medicines regulatory agency’s (NMRA) responsibility.
Throughout this WHOPAR the proprietary name is given as an example only.
Page 2 of 7
Amodiaquine( as hydrochloride) 153mg Dispersible Tablets + WHOPAR Part 3 January 2019
Pyrimethamine/Sulfadoxine 25mg/500mg Dispersible Tablets
(Guilin Pharmaceuticals Co., Ltd.) MA117
If you are not sure your child should be given SPAQ-CO® Disp 153mg+25mg/500mg, talk to your health
care provider before giving the medicine.
Your health care provider will tell you when to start treatment with SPAQ-CO® Disp 153mg+25mg/500mg.
To give the best protection your child should have a maximum of four courses of SPAQ-CO® Disp
153mg+25mg/500mg during the malaria season. Each course lasts 3 days and your health care provider
might give the medicines on the first day.
The doses recommended below are suitable for children aged 12 to 59 months.
Page 3 of 7
Amodiaquine( as hydrochloride) 153mg Dispersible Tablets + WHOPAR Part 3 January 2019
Pyrimethamine/Sulfadoxine 25mg/500mg Dispersible Tablets
(Guilin Pharmaceuticals Co., Ltd.) MA117
If your child vomits within 30 minutes of taking the tablet then you may need to give another tablet. Wait
for 10 minutes before giving the replacement dose.
If you have any questions on the use of this medicine, ask your health care provider.
If your child is given more SPAQ-CO® Disp 153mg+25mg/500mg than the child should have
If your child has been given too much SPAQ-CO® Disp 153mg+25mg/500mg, tell your health care provider.
If your child does not get SPAQ-CO® Disp 153mg+25mg/500mg at the right time
Your child should take the medicines at the right time to have the best chance of preventing malaria. If your
child misses a dose, give the missed dose as soon as you can and give the next one after at least 8 hours. If
your child misses a full course (a month after the previous one) then the child will be less well protected but
your child should still receive the next course.
Like all medicines, this medicine can cause side effects but not everybody gets them.
Page 4 of 7
Amodiaquine( as hydrochloride) 153mg Dispersible Tablets + WHOPAR Part 3 January 2019
Pyrimethamine/Sulfadoxine 25mg/500mg Dispersible Tablets
(Guilin Pharmaceuticals Co., Ltd.) MA117
The most common side effects of amodiaquine are vomiting, stomach pain, fever, diarrhoea, itching,
headaches and rash. Pyrimethamine/sulfadoxine can cause skin rash and side effects on moist areas such as
the lining of the nose and the mouth.
Serious but rare side effects include blood disorder, liver damage and severe skin reactions.
Other side effects have occurred with amodiaquine and pyrimethamine/sulfadoxine usually in adults treated
for malaria but not when these medicines are used for seasonal malaria prevention in children. These side
effects include:
Digestive system
Loss of appetite, feeling sick, inflammation of the tongue and in the mouth, stomach feeling full
Skin
Skin reactions caused by sunlight, slight hair loss, grey coloration of the skin and the lining of the nose,
mouth, etc,
Eyes
Temporary problems with focussing, clouding of the clear layer at the front of the eye (which gets better
when the medicine is stopped), damage to the light-sensitive layer at the back of the eye, swelling around the
eyes, and redness
Ear
Ringing or buzzing sound in the ear, sense of losing balance or feeling giddy
Heart
Inflammation of the heart and of the sac that surrounds the heart
Allergic reactions
Allergic reactions including skin rashes, joint stiffness and fever, swelling of the throat, face, and other parts
of the body
Bones
Joint pain
Lungs
Allergic reactions in the lungs
Reporting of side effects
If you get any side effects,talk to your health care provider. This includes unwanted effects not listed in this
leaflet.If available, you can also report side effects directly through the national reporting system. By
reporting side effects you can help provide more information on the safety of this medicine.
Page 5 of 7
Amodiaquine( as hydrochloride) 153mg Dispersible Tablets + WHOPAR Part 3 January 2019
Pyrimethamine/Sulfadoxine 25mg/500mg Dispersible Tablets
(Guilin Pharmaceuticals Co., Ltd.) MA117
Do not store above 30oC, store the tablets in blisters in the provided box/carton. Protect from light.
Do not use this medicine after the expiry date stated on the pack.
Do not throw away any medicines in wastewater or household waste. Ask your health care provider how to
throw away medicines you no longer use. These measures will help protect the environment.
What SPAQ-CO® Disp 153mg+25mg/500mg looks like and contents of the pack
On both tablets, the score lines are only to facilitate breaking for ease of swallowing and not to divide into
equal doses.
The tablets are packaged in colourless transparent PVC/Al blister containing three Amodiaquine (as
hydrochloride) 153mg dispersible tablets and one Pyrimethamine/Sulfadoxine 25mg/500mg dispersible
tablet.
Page 6 of 7
Amodiaquine( as hydrochloride) 153mg Dispersible Tablets + WHOPAR Part 3 January 2019
Pyrimethamine/Sulfadoxine 25mg/500mg Dispersible Tablets
(Guilin Pharmaceuticals Co., Ltd.) MA117
For any information about this medicine, contact the local representative of the supplier:
Detailed information on this medicine is available on the World Health Organization (WHO) web site:
https://extranet.who.int/prequal/.
Page 7 of 7